Study on antitumor effects of p16 and granulocyte macrophage-colony stimulating factor combined gene therapy for renal carcinoma

王林辉,孙颖浩,钱松溪,闵志廉,弭静,鞠佃文,曹雪涛

DOI: https://doi.org/10.3760/j.issn:1001-9030.2000.03.008

2000-01-01

Abstract:Objective To investigate the antitumor effects of p16 and GM CSF combined gene therapy for renal cell carcinoma (renca) and elucidate the immune mechanisms of its antitumor response. Methods The model of renal tumor bearing mice by injected subcutaneously was developed. The tumor bearing mice were grouped as 5 groups at random 3 days after injection of Renca cells. Different groups of the mice were subjected to different treatments. The antitumor immune responses and the survival time of the mice were tested. Histopathologic analysis of tumor tissue was performed. Results The mice receiving combined therapy of AdP16+AdGM CSF were able to survive much longer than all the other mice receiving control therapies ( P 0.01). Two of 10 mice after AdP16/AdGM CSF combined therapy were found to be tumor free and lived more than 90 days, while the control animals died within 52 days. Enhancement of the NK cytotoxicity (33%) were observed more obviously in tumor bearing mice after combined therapy when compared with that of the other 4 groups ( P 0.01). Conclusion p16 and GM CSF combined gene therapy can enhance the antitumor immune responses of mice and inhibit the growth of pre established renal cell carcinoma, also prolong the survival time of tumor bearing mice.\;